Prostatic intraepithelial neoplasia

被引：39

作者：

Bostwick D.G. ^{[1
]}

机构：

[1] Bostwick Laboratories, 6722 Patterson Avenue, Richmond, 23226, VA

来源：

Current Urology Reports | 2000年 / 1卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Androgen Deprivation Therapy; Finasteride; Prostate Cancer; Prostatic Intraepithelial Neoplasia; Radical Prostatectomy;

D O I：

10.1007/s11934-000-0037-x

中图分类号：

学科分类号：

摘要：

High-grade prostatic intraepithelial neoplasia (PIN) is now accepted as the most likely pre-invasive stage of adenocarcinoma, a decade after its first formal description. PIN has a high predictive value as a marker for adenocarcinoma, and its identification warrants repeat biopsy for concurrent or subsequent invasive carcinoma. The only method of detection is biopsy; PIN does not significantly elevate serum prostate-specific antigen concentration or its derivatives and cannot be detected by ultrasound. Most studies suggest that most patients with PIN will develop carcinoma within 10 years. PIN is associated with progressive abnormalities of phenotype and genotype that are similar to cancer rather than normal prostatic epithelium, indicating impairment of cell differentiation with advancing stages of prostatic carcinogenesis. Androgen deprivation therapy decreases the prevalence and extent of PIN, suggesting that this form of treatment may play a role in chemoprevention. © 2002, Current Science Inc.

引用

页码：65 / 70

页数：5

共 50 条

[41]

Poczatek R.B., Myers R.B., Manne U., Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia, J Urol, 162, pp. 1462-1466, (1999)

[42]

Bostwick D.G., Pacelli A., Blute M., Et al., Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer, 82, pp. 2226-2256, (1998)

[43]

Bonkhoff H., Fixemer T., Hunsicker I., Remberger K., Estrogen receptor expression in prostate cancer and premalignant prostatic lesions, Am J Pathol, 155, pp. 641-647, (1999)

[44]

Leav I., Merk F.B., Lee K.F., Et al., Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions, Am J Pathol, 154, pp. 863-870, (1999)

[45]

Balaji K.C., Rabbani F., Tsai H., Et al., Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance, J Urol, 162, pp. 753-757, (1999)

[46]

Ferguson J., Zincke H., Ellison E., Et al., Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy, Urology, 44, pp. 91-95, (1994)

[47]

Yang X.J., Lecksell K., Short K., Et al., Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?, Urology, 53, pp. 696-700, (1999)

[48]

Cheng L., Cheville J.C., Pisansky T.M., Et al., Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy, Am J Surg Pathol, 23, pp. 803-808, (1999)

[49]

Holash J., Maisonpierre P.C., Compton D., Et al., Vessel cooption, regression, and growth mediated by angiopoietins and VEGF, Science, 284, pp. 1994-1999, (1999)

[50]

Bostwick D.G., Neumann R., Qian J., Cheng L., Reversibility of prostatic intraepithelial neoplasia: Implications for chemoprevention, Eur Urol, 35, pp. 492-495, (1999)

← 1 2 3 4 5 →